Results 131 to 140 of about 5,159 (158)

Barriers and Facilitators to the Use of Novel Injectable Lipid-Lowering Therapies in Patients with Dyslipidemia or Cardiovascular Disease: A Scoping Review. [PDF]

Medicina (Kaunas)
Caggianelli G, Iorfida M, Cavaliere R, Manzoli A, D'Angelo A, Scerbo F, Marti F, Mancin S, Cangelosi G, Rocco G, Vanzi V, Karuveettil V, Zega M, Donnoli C.   +13 more
europepmc   +1 more source

Impact of PCSK9 inhibitor on T lymphocyte subsets and cytokines in patients with acute ischemic stroke: an exploratory analysis of a randomized clinical trial. [PDF]

Front Neurol
Liu J, Han C, Ji X, Cao H, Chen S, Tan C, Hao X, Joyama Y, Zou W, Li Y, Liu J.   +10 more
europepmc   +1 more source

A disproportionality analysis on proprotein convertase subtilisin/kexin type 9 inhibitors and hypersensitivity and anaphylaxis. [PDF]

Sci Rep
Dermiki-Gkana F, Gravel CA, Kontogiorgis C, Douros A.   +3 more
europepmc   +1 more source

PCSK9 Promotes Platelet Activation and NET Formation, Aggravating Pulmonary Microthrombosis in Sepsis-Induced Lung Injury. [PDF]

Biomedicines
Lv X, Xiong W, Jiang L.
europepmc   +1 more source

Genetic association between PCSK9 and coronary artery calcification mediated by inflammatory cytokines. [PDF]

Front Cardiovasc Med
Wang W, Ye J, Hu X, Chen Z, Wang L, Chen L.   +5 more
europepmc   +1 more source

Effects of PCSK9 inhibitors on vascular function, lipid profile, and cardiovascular outcomes in patients with peripheral artery disease: A systematic review and meta-analysis. [PDF]

Int J Cardiol Cardiovasc Risk Prev
Hamzah KA, Kurmasha YH, Abdrabo MF, Srour MF, Al-Shammari AS, Badi MHI, Shweliya MA, Jena N, Sattar Y.   +8 more
europepmc   +1 more source

Choosing the Right Non-Statin Therapy for the Right Patient - How To Sequence Advanced Lipid-Lowering Therapies. [PDF]

Curr Atheroscler Rep
Katzmann JL, Laufs U.
europepmc   +1 more source

Evolocumab, a PCSK9 inhibitor, protects human endothelial cells against H2O2-induced oxidative stress

Archives of Physiology and Biochemistry, 2022
CONTEXT: Recent surveys have shown an association between proprotein convertase subtilisin/kexin type 9 (PCSK9) and oxidative stress. OBJECTIVE: In this investigation, the effect of evolocumab an anti-PCSK9 antibody was assessed against oxidative damage ...
Leila Safaeian, Mina Mirian
exaly   +2 more sources

Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain

Clinical Therapeutics, 2017
Purpose Our objective was to assess the cost-effectiveness of evolocumab in patients at high risk of cardiovascular (CV) events from the Spanish National Health System perspective. Methods A Markov model was used to assess the cost-effectiveness
Guillermo Villa, Mickael Lothgren, Lucie Kutikova   +2 more
exaly   +2 more sources